160 related articles for article (PubMed ID: 3737445)
1. Central injections of arginine vasopressin prolong extinction of active avoidance.
Koob GF; Dantzer R; Bluthé RM; Lebrun C; Bloom FE; Le Moal M
Peptides; 1986; 7(2):213-8. PubMed ID: 3737445
[TBL] [Abstract][Full Text] [Related]
2. Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats.
Koob GF; Le Moal M; Gaffori O; Manning M; Sawyer WH; Rivier J; Bloom FE
Regul Pept; 1981 Jun; 2(3):153-63. PubMed ID: 7255768
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin pressor antagonist injected centrally reverses behavioral effects of peripheral injection of vasopressin, but only at doses that reverse increase in blood pressure.
Lebrun C; Le Moal M; Koob GF; Bloom FE
Regul Pept; 1985 Jun; 11(2):173-81. PubMed ID: 4035008
[TBL] [Abstract][Full Text] [Related]
4. Vasopressin antagonists block peripheral as well as central vasopressin receptors.
De Wied D; Gaffori O; Van Ree JM; De Jong W
Pharmacol Biochem Behav; 1984 Sep; 21(3):393-400. PubMed ID: 6093152
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin analgesia: specificity of action and non-opioid effects.
Kordower JH; Bodnar RJ
Peptides; 1984; 5(4):747-56. PubMed ID: 6494025
[TBL] [Abstract][Full Text] [Related]
6. Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?
de Wied D; Elands J; Kovács G
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1494-8. PubMed ID: 1847526
[TBL] [Abstract][Full Text] [Related]
7. Effects of vasopressin and analogue [d(CH2)1(5), Tyr (Me)2, Val4, delta 3Pro7)] AVP on learning and memory in rats chronically treated with ethanol.
Car H; Borawska MH; Wiśniewski K
J Physiol Pharmacol; 1994 Mar; 45(1):163-71. PubMed ID: 8043905
[TBL] [Abstract][Full Text] [Related]
8. EEG effects of subcutaneous and intracerebroventricular injections of arginine vasopressin in the rat.
Ehlers CL; Reed TK; Wang M; Lebrun CJ; Koob GF
Psychopharmacology (Berl); 1985; 87(4):430-3. PubMed ID: 3936102
[TBL] [Abstract][Full Text] [Related]
9. Chronic intracerebral infusions of vasopressin and vasopressin antagonist modulate behavioral effects of interleukin-1 in rat.
Bluthé RM; Dantzer R
Brain Res Bull; 1992 Dec; 29(6):897-900. PubMed ID: 1473021
[TBL] [Abstract][Full Text] [Related]
10. Pinealectomy blocks modulation of active avoidance by central vasopressin application in rats.
Appenrodt E; Schwarzberg H
Peptides; 2003 Jan; 24(1):129-36. PubMed ID: 12576094
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic icv infusion of vasopressin on sleep-waking cycle of rats.
Arnauld E; Bibene V; Meynard J; Rodriguez F; Vincent JD
Am J Physiol; 1989 Mar; 256(3 Pt 2):R674-84. PubMed ID: 2923256
[TBL] [Abstract][Full Text] [Related]
12. Enhanced pressor responses to ICV vasopressin after pretreatment with oxytocin.
Poulin P; Komulainen A; Takahashi Y; Pittman QJ
Am J Physiol; 1994 Feb; 266(2 Pt 2):R592-8. PubMed ID: 8141420
[TBL] [Abstract][Full Text] [Related]
13. Participation of arginine vasopressin-mediated and adrenergic system-mediated mechanisms in the hypertension induced by intracerebroventricular administration of NMDA in freely moving rats.
Maione S; Vitagliano S; Berrino L; Lampa E; Rossi F
Neuropharmacology; 1992 Apr; 31(4):403-7. PubMed ID: 1355901
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of effects of vasopressin (AVP) on inhibitory avoidance by a vasopressin antagonist peptide [dPtyr(Me)AVP].
LeBrun CJ; Rigter H; Martinez JL; Koob GF; Le Moal M; Bloom FE
Life Sci; 1984 Oct; 35(14):1505-12. PubMed ID: 6482669
[TBL] [Abstract][Full Text] [Related]
15. Intraventricular administration of arginine vasopressin suppresses prolactin release via a dopaminergic mechanism.
DePaolo LV; Berardo PV; Carrillo AJ
Peptides; 1986; 7(3):541-4. PubMed ID: 3774591
[TBL] [Abstract][Full Text] [Related]
16. Hypothalamic blood flow autoregulation remains unaltered following surgical and pharmacological blockade of central vasopressin.
Sandor P; Petty M; de Jong W; Palkovits M; de Wied D
Brain Res; 1991 Dec; 566(1-2):212-8. PubMed ID: 1814538
[TBL] [Abstract][Full Text] [Related]
17. Preventive effect of cholecystokinin octapeptide on experimental amnesia in rats.
Katsuura G; Itoh S
Peptides; 1986; 7(1):105-10. PubMed ID: 3714527
[TBL] [Abstract][Full Text] [Related]
18. Specificity of aversive stimulus properties of vasopressin.
Bluthé RM; Dantzer R; Mormède P; Le Moal M
Psychopharmacology (Berl); 1985; 87(2):238-41. PubMed ID: 3931152
[TBL] [Abstract][Full Text] [Related]
19. Central vasopressin pretreatment sensitizes phosphoinositol hydrolysis in the rat septum.
Lebrun CJ; Gruber MG; Meister M; Unger T
Brain Res; 1990 Oct; 531(1-2):167-72. PubMed ID: 1963099
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
